The remission of Cushing's syndrome following sur-
INTRODUCTION
The amphibian skin tetradecapeptide bombesin (Anastasi, Erspamer & Bucci, 1971) and its mammalian counterpart, the porcine heptacosapeptide gastrinreleasing peptide (GRP) ( Fig. 1) (Erspamer, Melchiorri, Falconier-Erspamer & Negri, 1978; McDonald, 1981) . The presence of bombesin-like immunoreactivity (BLI) in the mammalian hypothalamus (Brown, Allen, Villarreal et al. 1978 ) and the identification of pituitary cell bombesin receptors (Westendorf & Schonbrunn, 1983 ) indicate a possible role for bombesin-like peptides in the control of the pituitary. The effects of bombesin on anterior pit¬ uitary hormone secretion are controversial. In the rat it has been reported to stimulate growth hormone and prolactin release both in vivo and in vitro (Westendorf & Schonbrunn, 1982) . However, in man, although prolactin release has been reported (Pontirolli, Alberetto, Restelli & Fachinetti, 1980) , there has been a failure to demon¬ strate any effect of bombesin on the secretion of a number of the other anterior pituitary hormones (Morley, Varner, Modi in et al. 1980) . The ACTH releasing bioactivity of the tumour tissue and synthetic GRP(14-27) was studied using the isolated rat anterior pituitary cell column (Gillies & Lowry, 1978) . Cells were prepared as described for tumour cells. Pulsed doses of the acid extract of the tumour were compared with synthetic oCRF-41 (10-90 ng/ml) and the CRF activity of a rat stalk median eminence extract (SME). GRP(14-27) was tested alone in doses from 10-1000 ng/ml.
Two columns were set up in parallel, one as con¬ trol to examine the effect of a continuous perfusion of GRP(14-27) at doses which, in themselves (10-1000 pg/ml), did not cause ACTH release. After stim¬ ulation of each column with doses of oCRF-41 (10-90 pg/ml), GRP(14-27) was added to the perfusion medium of the test column. Both columns were stim¬ ulated with 3-min pulses of oCRF-41 (30 ng/ml) which continued after the infusion of GRP has ceased.
Finally columns were stimulated with 3-min pulses of oCRF-41 (10-90 ng/ml) alone, or with a constant dose of GRP(14-27) at a sub-thresold level.
RESULTS
Peptide levels in the tumour extract The concentration of ACTH (0.018 ng/mg) was considerably less than normally found in ectopie ACTH-secreting tumours (1.03±0.63 ng/mg) (Ratcliffe, Knight, Besser et al. (1972 (Fig. 2) .
Bioactivity of GRP(14-27) on isolated rat pituitary cells Supraphysiological doses of synthetic GRP(14-27) (10-1000 ng/ml) stimulated ACTH release in a linear dose-dependent manner (Fig. 3) . The BLI con¬ tent of tumour extract producing a 500% increase over basal level was 56 ng. Continuous perfusion with GRP(14-27), in doses themselves insufficient to release ACTH (10-1000 pg/ ml), in conjunction with simultaneous stimulation with 3-min pulses of CRF (30 ng/ml), resulted in a 100% increase in the ACTH response to CRF. A carry¬ over effect was observed, until the response returned to that of the control column. However, this effect was not dependent upon the dose of GRP(14-27) per¬ fused (Fig. 4) . Stimulation with 3-min pulses of a combined dose of oCRF-41 (10-90 pg/ml) and GRP(14-27) (100 pg/ml) resulted in an increase of ACTH release of approx¬ imately 50% over that released by the equivalent dose of oCRF-41 alone (Fig. 5) (Vale, Speiss, Rivier & Rivier, 1981) has been shown to stimulate the release of ACTH, ß-LPH and ß-from cultured anterior pituitary cells. The action of this peptide is potentiated several times by AVP (Bény & Baertschi, 1982) and also by AVP-free hypothalamic extracts, confirming that an additional factor or factors may be involved in the complex (Gillies, Linton & Lowry, 1982) .
From our clinical observations and subsequent in-vitro experiments, we propose that GRP, the mam¬ malian counterpart of amphibian bombesin, may be involved in the CRF complex and deserves further investigation.
